NCT02109627 - Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 1, 2015

Primary Completion Date

December 2, 2019

Study Completion Date

December 2, 2019

Conditions

Acute Myeloid LeukemiaRelapsed Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia

Interventions

DRUG

Ficlatuzumab

5-20 mg/kg; intravenous; Days 0, 14, 28, and 42. Number of cycles: until progression or unacceptable toxicity develops.

DRUG

Cytarabine

2 g/m2; intravenous; Days 2-7; Number of cycles: until progression or unacceptable toxicity develops.

Trial Locations (1)

University of California, San Francisco, San Francisco